SCImago Journal & Country Rank
This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE)
2018, Volume 34, Number 3, Page(s) 199-206     
[ PDF ] [ Similar Articles ]
DOI: 10.5146/tjpath.2018.01430
Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma
Aydan KILIÇARSLAN1 , Vedia ÖZTÜRK2, Aysun ŞENTÜRK YIKILMAZ3, Mehmet DOĞAN4, Mesut AKYOL5
1Department of Pathology, Ankara Yıldırım Beyazıt University, School of Medicine, ANKARA, TURKEY
2Van Education and Research Hospital, VAN, TURKEY
3Department of Hematology, Ankara Atatürk Education and Research Hospital, ANKARA, TURKEY
4Department of Pathology, Ankara Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, ANKARA, TURKEY
5Department of Biostatistic, Ankara Yıldırım Beyazıt University, School of Medicine, ANKARA, TURKEY
Keywords: Hodgkin lymphoma, c-Myc, Bcl-2, EBER

Objective: Although classical Hodgkin lymphoma (cHL) has a relatively good prognosis, it also entails different treatment responses and involves patients who have different clinical courses. Our aim was to investigate c-Myc, Bcl-2 and EBV biomarkers in cHL and their relationship with the IPS score.

Material and Method: c-Myc and Bcl-2 immunohistochemical staining with EBER in situ hybridization (EBER-ISH) was applied to the paraffin sections of 94 cases diagnosed as cHL. These cases were classified into two groups as low and high clinical symptoms according to the International Prognostic Scores (IPS).

Results: Positive results were obtained in 83 (88.3%) cases with c-Myc and 39 (43.5%) cases with Bcl-2 while EBER-ISH was found positive in 42 (44.7%) cases. No difference was found between the groups of low/high IP scores with respect to the positive or negative results of EBER-ISH, Bcl-2 and c-Myc. When Bcl-2 and c-Myc positive cases were grouped together and compared to the IP scores of the remaining cHL cases, again no difference was seen. Extranodal involvement and bone marrow involvement was observed in 25 (26.5%) and 9 (9.5%) cases, respectively. Similarly, no statistically significant differences was found between these groups according to their positivity with EBER-ISH, Bcl-2 and c-Myc.

Conclusion: We could not find any relationship between Bcl-2, c-Myc and EBER-ISH positivity and the low/high IPS groups in cHL. New studies with larger series are needed in which more precise cut-off values are used and clinically and biologically heterogeneous groups of cHL patients are determined more clearly.


[ PDF ] [ Similar Articles ]